KPCB XV Associates
Latest statistics and disclosures from KPCB XV Associates's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RAPT, TWLO, Atara Biotherapeutics, and represent 100.00% of KPCB XV Associates's stock portfolio.
- Reduced shares in these 2 stocks: RAPT (-$16M), AUGX.
- Sold out of its position in AUGX.
- KPCB XV Associates was a net seller of stock by $-16M.
- KPCB XV Associates has $36M in assets under management (AUM), dropping by -33.90%.
- Central Index Key (CIK): 0001547838
Tip: Access up to 7 years of quarterly data
Positions held by KPCB XV Associates consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for KPCB XV Associates
KPCB XV Associates holds 3 positions in its portfolio as reported in the September 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Rapt Therapeutics Common Stock (RAPT) | 43.5 | $16M | -50% | 649k | 24.06 |
|
| Twilio Class A Common Stock (TWLO) | 36.7 | $13M | 190k | 69.14 |
|
|
| Atara Biotherapeutics Common Stock | 19.8 | $7.1M | 1.9M | 3.78 |
|
Past Filings by KPCB XV Associates
SEC 13F filings are viewable for KPCB XV Associates going back to 2020
- KPCB XV Associates 2022 Q3 filed Oct. 26, 2022
- KPCB XV Associates 2022 Q2 filed July 21, 2022
- KPCB XV Associates 2022 Q1 filed May 13, 2022
- KPCB XV Associates 2021 Q4 filed Feb. 14, 2022
- KPCB XV Associates 2021 Q3 filed Oct. 25, 2021
- KPCB XV Associates 2021 Q2 filed July 28, 2021
- KPCB XV Associates 2021 Q1 filed May 13, 2021
- KPCB XV Associates 2020 Q4 filed Feb. 16, 2021